Relationship between T2 biomarkers and clinical remission in severe T2 high asthmatics after 12 months of treatment with omalizumab, mepolizumab and benralizumab. - Vienna 2024

Response to biologics in severe asthma: moving forwards

Chair(s): Christopher E. Brightling, Giuseppe Guida

Session type: Poster session

Relationship between T2 biomarkers and clinical remission in severe T2 high asthmatics after 12 months of treatment with omalizumab, mepolizumab and benralizumab.

Mare Sabbe

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Assessment of asthma control identifies new super responders to anti-IL5r therapy in severe asthma

Ga Tavernier

Poster

Abstract

COGNITIVE IMPAIRMENT IN SEVERE ASTHMA LONG-TERM EFFECTS OF BIOLOGICALS

Charlotte Bernhoff

Poster

Abstract

ROLE OF SUBACUTE BRONCHIAL INFECTION IN PATIENTS WITH SEVERE ASTHMA CANDIDATES FOR BIOLOGIC THERAPY

Mireia Vicens

Poster

Abstract

Biologics in severe eosinophilic asthma treatment: four years of a single-centre follow-up

Borislav Bo?ani?

Poster

Abstract

Relationship between knowledge, adherence and self-management with response to monoclonal antibody therapy in patients with severe asthma

Christopher Alexander Hinze

Poster

Abstract

Understanding patient perception of asthma biologic treatment response

Sunera Khan

Poster

Abstract

Eosinophilic phenotype in adults with severe asthma in a tropical middle-income country: The ISAR Colombia experience

Carlos A Torres-duque

Abstract

HRCT chest findings in Th2 high severe asthma patients considered for biological therapies.

Collin Mattathil

Poster

Abstract

Predictors of new-onset EGPA in patient with severe asthma treated with anti IL-4/13

Greta Insalata

Poster

Abstract

Relationship between T2 biomarkers and clinical remission in severe T2 high asthmatics after 12 months of treatment with omalizumab, mepolizumab and benralizumab.

Mare Sabbe

Poster

Abstract

Real-world clusters of severe asthma from the Italian Registry on Severe Asthma (IRSA): a longitudinal Latent Class Analysis

Matteo Martini

Poster

Abstract

Evaluation of Asthma Control And Treatment Adherance In Asthma Patients

G?listan Karadeniz

Poster

Abstract

Prevalence of Asthma Remission in CSAR Cohort

Saud Almousa

Poster

Abstract

Title: Do older patients with severe asthma respond to asthma biologics?

Wint Wah Soe

Poster

Abstract

Real-world changes in fatigue in severe asthma patients after starting anti-interleukin-4/13 biologic

Lianne Ten Have

Poster

Abstract

Hydrogen peroxide as a potential marker for monitoring airway inflammation in severe asthma patients on biologics

Claudia Gagliani

Poster

Abstract

The effect of biological treatment on small airways function of patients with severe asthma

Anastasia Siora

Poster

Abstract

Characteristics and evolution of patients treated with Biologicals in severe asthma of Getafe University hospital

Alejandro Garc?a Garc

Poster

Abstract

Evaluation of dupilumab and benralizumab on peripheral airway resistance and reactance in type 2 high severe asthma

Rory Chan

Poster

Abstract

Effectiveness of dupilumab on lung function in severe eosinophilic asthma

Joana Filipe Marques Sim?es

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}